secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001739410-23-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reports Q3 2023 net loss of $18.4M ($0.45/share); cash $121.4M, runway into Q1 2025
--------------------------------------------------------------------------------

- Net loss of $18.4M, or $0.45 per share, unchanged from Q3 2022 net loss of $18.4M ($0.60 per share).
- R&D expenses $13.3M (up vs $12.1M in Q3 2022) on advancing RLYB212 and RLYB331; G&A expenses $6.1M (down from $6.8M).
- Cash, cash equivalents and marketable securities $121.4M as of Sept 30, 2023; expected to fund operations into Q1 2025.
- On track for 4Q 2023 data readouts: RLYB212 Phase 1 multiple dose cohort initial data and RLYB116 Phase 1 MAD data including safety, PK, PD.
- RLYB212 Phase 2 dose confirmation study in pregnant women expected to initiate in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/0001739410-23-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000011/rlyb-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001739410-23-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer